Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
Last trade$4.04
Day change-$0.005 (-0.12%)
Day range$3.75 – $4.37
Volume886,764
Market cap$619M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$619.3M
Price / earnings
2.82×
Price / book
7.22×
Price / sales
3.41×
EV / sales
1.97×
EV / EBITDA
2.43×
Profitability
Earnings per share
$1.43
Return on assets
64.72%
Return on equity
256.41%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.03×
Current ratio
1.4×
Quick ratio
1.4×
Cash ratio
1.09×
Cash flow
Price / cash flow
2.8×
Price / free cash flow
2.8×
Free cash flow
$221M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ABUS, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$299K
$1.01M
$179.13M
$1.05M
$529K
$10.74M
$1.76M
$1.57M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$299K
$1.01M
$179.13M
$1.05M
$529K
$10.74M
$1.76M
$1.57M
Selling, general and administrative
$7.96M
$3.87M
$5.89M
$3.69M
$3.04M
$3.33M
$5.83M
$4.71M
Research and development
$2.62M
$2.9M
$4.12M
$5.01M
$5.78M
$5.5M
$8.96M
$8.81M
Total operating expenses
$10.79M
$6.98M
$10.22M
$6.34M
$9.19M
$9.25M
$27.46M
$15.51M
Operating income
-$10.49M
-$5.96M
$168.91M
-$5.29M
-$8.66M
$1.49M
-$25.7M
-$13.93M
Interest expense
-$11K
-$18K
-$17K
-$18K
-$23K
-$28K
-$28K
-$30K
Income before taxes
$59.12M
-$5.19M
$169.7M
-$3.76M
-$7.74M
$2.5M
-$24.53M
-$12.53M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
$59.12M
-$5.19M
$169.7M
-$3.76M
-$7.74M
$2.5M
-$24.53M
-$12.53M
Net income attributable to common shareholders
$59.12M
-$5.19M
$169.7M
-$3.76M
-$7.74M
$2.5M
-$24.53M
-$12.53M
EBITDA
-$10.48M
-$5.95M
$168.92M
-$4.98M
-$8.55M
$1.66M
-$13M
-$13.51M
Basic earnings per share
$0.30
-$0.03
$0.88
-$0.02
-$0.04
$0.01
-$0.13
-$0.07
Diluted earnings per share
$0.30
-$0.03
$0.87
-$0.02
-$0.04
$0.01
-$0.13
-$0.07
Recent news
Company coverage with links to the original publishers.
Moderna exceeded Q3 earnings expectations with 38 cents EPS versus an estimated loss of $1.10, driven by 29.2% revenue growth to $1.31 billion from international COVID-19 vaccine sales. The company raised its 2026 revenue growth target to 15-25% and reduced R&D spending plans to $2.7 billion. The stock surged in pre-market trading, with year-to-date gains exceeding 700%.
Moderna settled a long-running legal dispute over COVID-19 vaccine technology, paying $2.25 billion to Roivant Sciences' Genevant unit and Arbutus Biopharma—less than the $3 billion expected. While Moderna stock surged 15.99% on the news, analysts suggest it now trades 22% above fair value after a 108% six-month rally. The article identifies 9 biotech stocks trading 27.6% to 64.6% below fair value with potential upside of 31.6% to 251.4%.
Moderna reached a $950 million settlement agreement with Arbutus Biopharma and Roivant's Genevant Sciences, resolving litigation related to its COVID-19 vaccine Spikevax and mRESVIA product. The settlement clears a major legal overhang, allowing the company to focus on future growth. Moderna expects to end 2026 with $4.5-5 billion in cash and aims for breakeven in 2028. The stock surged 8.85% in premarket trading as the settlement value was better than investors' worst-case fears.
Moderna's stock has been struggling since the end of the COVID-19 pandemic, with a Wall Street analyst cutting her price target and reiterating a sell recommendation. The analyst cited issues such as cost-management struggles and legal headaches, as well as a hold on a late-stage trial for a norovirus vaccine candidate.
Ultragenyx (RARE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.